European Journal of CancerThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

1026 records returned

CalendarEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - November 1, 2009 Category: Cancer & Oncology Source Type: journals

Ejc news, issue 17, 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - November 1, 2009 Category: Cancer & Oncology Source Type: journals

Editorial boardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - November 1, 2009 Category: Cancer & Oncology Source Type: journals

CalendarEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - October 23, 2009 Category: Cancer & Oncology Source Type: journals

Ejc news, issue 16, 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - October 23, 2009 Category: Cancer & Oncology Source Type: journals

Editorial boardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - October 23, 2009 Category: Cancer & Oncology Source Type: journals

Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Aim: Ovarian epithelial dysplasia (OED) was first described after prophylactic oophorectomy for genetic risk of ovarian cancer. In light of Fathalla’s incessant ovulation theory, this study was set up to describe the presence of ovarian abnormalities (dysplasia) after ovulation induction and to compare dysplasia profiles in stimulated and genetic risk ovaries.Methods: One-hundred and twenty-four patients who had undergone salpingo-oophorectomies or ovarian cystectomies between 1990 and 2005 were reviewed. They were divided into three groups: (1) previous in vitro fertilisation (n=35); (2) prophylactic oophorect...
Source: European Journal of Cancer - October 12, 2009 Category: Cancer & Oncology Authors: J. Dauplat, G. Chene, C. Pomel, M.M. Dauplat, G.Le Bouëdec, F. Mishellany, N. Lagarde, Y.J. Bignon, P. Jaffeux, B. Aublet-Cuvelier, P. Dechelotte, J.L. Pouly, F. Penault-Llorca Tags: Clinical oncology Source Type: journals

MiRNA-29a regulates the expression of numerous proteins and reduces the invasiveness and proliferation of human carcinoma cell linesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study we have identified a functional role for miR-29a in cancer cell invasion and proliferation. MiRNA expression profiling of human NSCLC cell lines indicated that miR-29a levels were reduced in more invasive cell lines. Exogenous overexpression of miR-29a in both lung and pancreatic cancer cell lines resulted in a significant reduction in the invasion phenotype, as well as in proliferation. 2D DIGE proteomic profiling of cells transfected with pre-miR-29a or anti-miR-29a resulted in the identification of over 100 differentially regulated proteins. The fold change of protein expression was generally modest – in...
Source: European Journal of Cancer - October 9, 2009 Category: Cancer & Oncology Authors: M.K. Muniyappa, P. Dowling, M. Henry, P. Meleady, P. Doolan, P. Gammell, M. Clynes, N. Barron Tags: Experimental oncology Source Type: journals

Regulation of EP receptors in non-small cell lung cancer by epigenetic modificationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: These results indicate that EP expression is variably altered from tumour to tumour in NSCLC. EP2 expression appears to be predominantly downregulated and may have an important role in the pathogenesis of the disease. Epigenetic regulation of the EPs may be central to the precise role COX-2 may play in the evolution of individual tumours. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 9, 2009 Category: Cancer & Oncology Authors: Steven G. Gray, Nael Al-Sarraf, Anne-Marie Baird, Mary-Clare Cathcart, Eilish McGovern, Kenneth J. O’Byrne Tags: Experimental oncology Source Type: journals

The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour sizeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, the MPTA ratio of the antibody to the effector was found to be constant with tumour size, an observation that will simplify pretargeting optimisation because remeasurement of the optimum dosage ratio for different tumour sizes can be avoided. Theoretical considerations also suggest that this relationship may be universal for alternative antibody/effector pairs and for different target models, but this must be experimentally confirmed. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 7, 2009 Category: Cancer & Oncology Authors: Guozheng Liu, Shuping Dou, Minmin Liang, Xiangji Chen, Mary Rusckowski, Donald J. Hnatowich Tags: Experimental oncology Source Type: journals

Management of aggressive fibromatosis: Can we unravel the maze of treatment options?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The complexity and heterogeneity of aggressive fibromatosis (AF) is already reflected in its nomenclature. In addition to AF, desmoid tumour, desmoids, and desmoid-type fibromatosis are other names for the same entity. AF is a rare disease with an annual incidence of 2–4 per 1×106 people, and consists of a monoclonal proliferation of fibroblasts exhibiting infiltrative growth into adjacent structures, but without the ability to metastasise. Consequently, AF is classified as a benign disorder. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 5, 2009 Category: Cancer & Oncology Authors: Stefan Sleijfer Tags: Editorial comment Source Type: journals

Analysis of Ki-67 and Bcl-2 protein expression in normal colorectal mucosa of women with breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The aim of this study was to evaluate Ki-67 and Bcl-2 protein expression in the normal colorectal mucosa adjacent to adenomatous polyps in women with breast cancer. A cross-sectional, controlled study was conducted in 35 women with and without breast cancer who had adenomatous colorectal polyps. The patients were divided into two groups: Group A (a control group of women without breast cancer, n=18) and Group B (a study group of women with breast cancer, n=17). A sample of normal colonic mucosa was collected at a distance of 5cm from the polypoid lesion to evaluate immunohistochemical expression of the Ki-67 and ...
Source: European Journal of Cancer - September 28, 2009 Category: Cancer & Oncology Authors: Edílson C. Sousa-Júnior, Airlane P. Alencar, Benedito B. da Silva Tags: Experimental oncology Source Type: journals

Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Our study confirms that patients with favourable prognostic characteristics have a better survival. The use of sequential cycles of high-dose chemotherapy did not appear of benefit for patients with metastatic rhabdomyosarcoma. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 28, 2009 Category: Cancer & Oncology Authors: Gianni Bisogno, Andrea Ferrari, Arcangelo Prete, Chiara Messina, Eleonora Basso, Giovanni Cecchetto, Paolo Indolfi, Giovanni Scarzello, Paolo D’Angelo, Luigi De Sio, Andrea Di Cataldo, Modesto Carli Tags: Paediatric oncology Source Type: journals

Editorial boardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - September 23, 2009 Category: Cancer & Oncology Source Type: journals

Stereotactic body radiation therapy for liver metastasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Although resection is the standard of care for liver metastasis, 80–90% of patients are not resectable at diagnosis. Advances in combination chemotherapy, particularly with targeted agents, have increased tumour response and survival in patients with unresectable metastatic colorectal cancer, but these techniques have limitations and may be associated with high recurrence rates. Some autopsy series have shown that as many as 40% of patients with metastatic colorectal cancer have disease confined to the liver; aggressive local therapy may improve overall survival in such patients. Local control of liver metastas...
Source: European Journal of Cancer - September 23, 2009 Category: Cancer & Oncology Authors: Omar Dawood, Anand Mahadevan, Karyn A. Goodman Tags: Reviews Source Type: journals

Polymorphisms in telomere-associated genes, breast cancer susceptibility and prognosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Telomeres are essential structures for maintaining chromosomal stability and their length has been reported to correlate with cancer risk and clinical outcome. Single nucleotide polymorphisms (SNPs) in genes encoding telomere-associated proteins could affect telomere length and chromosomal stability by influencing gene expression or protein configuration in the telomeres. Here, we report the results of the first association study on genetic variation in telomere-associated genes and their effect on telomere length, breast cancer (BC) susceptibility and prognosis. We genotyped 14 potentially functional and most in...
Source: European Journal of Cancer - September 22, 2009 Category: Cancer & Oncology Authors: Verena Varadi, Annika Brendle, Andreas Brandt, Robert Johansson, Kerstin Enquist, Roger Henriksson, Ulrika Svenson, Björn Tavelin, Göran Roos, Kari Hemminki, Per Lenner, Asta Försti Tags: Clinical oncology Source Type: journals

Human papilloma virus in head and neck cancer: The need for a standardised assay to assess the full clinical importanceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Recent studies have revealed an important and intriguing role for human papillomavirus (HPV) in head and neck squamous cell carcinoma (HNSCC). There are indications that the prevalence of HPV-positive HNSCC has recently increased, and genetic analyses point to a completely distinct class of HNSCCs. Most studies suggest that patients with this type of tumour have a better prognosis and some argue that an adjusted therapeutic approach is needed. One crucial point in the research of HNSCC–HPV involvement has often been neglected, which is the lack of a standardised assay to detect HPV. This has resulted in a consi...
Source: European Journal of Cancer - September 22, 2009 Category: Cancer & Oncology Authors: Boudewijn J.M. Braakhuis, Ruud H. Brakenhoff, Chris J.L.M. Meijer, Peter J.F. Snijders, C. René Leemans Tags: Current perspective Source Type: journals

Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: This is the largest series of patients with AF receiving PLD reported to date. PLD as a single agent therapy has acceptable toxicity and highly promising activity in unresectable AF and may provide long-term clinical benefit in some patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 22, 2009 Category: Cancer & Oncology Authors: Anastasia Constantinidou, Robin L. Jones, Michelle Scurr, Omar Al-Muderis, Ian Judson Tags: Short communication Source Type: journals

Expert opinion in melanoma: The sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burdenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The sentinel node (SN) status has been recognised to be the most important prognostic factor in melanoma. Many studies have investigated additional factors to further predict survival/lymph node involvement. The EORTC Melanoma Group (MG) has formulated the following question: How should we report the microanatomic location and SN tumour burden?The EORTC MG recommends the following: the EORTC MG SN pathology protocol or a similarly extensive protocol, which has also been proven to be accurate, should be used. Only measure what you can see not what you presume. Cumulative measurements decrease the accuracy and repr...
Source: European Journal of Cancer - September 21, 2009 Category: Cancer & Oncology Authors: Alexander C.J. van Akkooi, Alain Spatz, Alexander M.M. Eggermont, Martin Mihm, Martin G. Cook Tags: Current perspective Source Type: journals

Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: This international study aimed to test the measurement properties of the updated European Organisation for Research and Treatment of Cancer (EORTC) questionnaire module for colorectal cancer, the QLQ-CR29.The QLQ-CR29 was administered with the QLQ-C30, core questionnaire, to 351 patients from seven countries. Questionnaire scaling and reliability were established and clinical and psychometric validity examined. Patient acceptability and understanding were assessed with a debriefing questionnaire.Multi-trait scaling analyses and face validity refined the module to four scales assessing urinary frequency, faecal se...
Source: European Journal of Cancer - September 18, 2009 Category: Cancer & Oncology Authors: R.N. Whistance, T. Conroy, W. Chie, A. Costantini, O. Sezer, M. Koller, C.D. Johnson, S.A. Pilkington, J. Arraras, E. Ben-Josef, A.M. Pullyblank, P. Fayers, J.M. Blazeby, on behalf of the European Organisation for the Research and Treatment of Cancer (EOR Tags: Clinical oncology Source Type: journals

The importance of early symptom recognition in the context of early detection and cancer survivalEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Since there is evidence that stage is an important prognostic factor in cancer, interventions aimed at ‘down-staging’ are part of a comprehensive cancer control approach. Besides organised screening programmes, raising awareness of detectable signs and symptoms is recommended.A precise definition of early cancer signs and symptoms, however, is lacking and there has also been no systematic review regarding the impact of awareness raising interventions on cancer outcomes.We reviewed the scientific medical literature to assess the consistency and availability of a definition for early cancer symptoms as well as ...
Source: European Journal of Cancer - September 17, 2009 Category: Cancer & Oncology Authors: J.J. Ott, A. Ullrich, A.B. Miller Tags: Position paper Source Type: journals

Are we there yet? The state of the evidence base for guidelines on breaking bad news to cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The way clinicians break bad news to cancer patients has been retrospectively associated with poor psychosocial outcomes for patients. Education and practice in breaking bad news may be ineffective for improving patients’ well-being unless it is informed by a sound evidence base. In the health field, research efforts are expected to advance evidence over time to inform evidence-based practice. Key characteristics of an advancing evidence base are a predominance of new data, and rigorous intervention studies which prospectively demonstrate improved outcomes. This review aimed to examine the progress of the evide...
Source: European Journal of Cancer - September 17, 2009 Category: Cancer & Oncology Authors: C.L. Paul, T. Clinton-McHarg, R.W. Sanson-Fisher, H. Douglas, G. Webb Tags: Reviews Source Type: journals

Contemporary pre-clinical development of anticancer agents – What are the optimal preclinical models?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The successful identification of novel effective anticancer drugs is largely dependent on the use of appropriate preclinical experimental models that should possibly mimic the complexity of different cancer diseases. The huge number of targets suitable for the design of new anticancer drugs is producing hundreds of novel molecules that require appropriate experimental models to investigate their mode of action and antitumour activity in order to select for clinical investigation the ones with higher chances of being clinically effective. However, our ability to predict the clinical efficacy of a new compound in t...
Source: European Journal of Cancer - September 16, 2009 Category: Cancer & Oncology Authors: Giovanna Damia, Maurizio D’Incalci Tags: Reviews Source Type: journals

Anal cancer: One step forward – Two steps sideways!Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Someone, or nobody, knows I wotWho or which or why or whatIs the Akond of Swat! The final verse of Edward Lear’s non-sense poem ‘The Akond of Swat’ could well describe our increasingly slippery grasp on how to improve the current treatment of anal cancer, which continues to elude us. Several recent trials have tantalisingly provided negative results – although overall results appear to be improving. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 16, 2009 Category: Cancer & Oncology Authors: R. Glynne-Jones Tags: Editorial comment Source Type: journals

Cardiac or cardiopulmonary transplantation in childhood cancer survivors: An increasing need?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study demonstrates that, over three decades, there has been an increased requirement for cardiac transplantation among childhood cancer survivors. Future planning for long term survivors needs to take this into account. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 10, 2009 Category: Cancer & Oncology Authors: Gill Levitt, Antoinette Anazodo, Michael Burch, Kathryn Bunch Tags: Paediatric oncology Source Type: journals

The value of surveillance mammography of the contralateral breast in patients with a history of breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Mammography is a valuable tool for the early detection of MCBC during hospital follow-up of breast cancer patients and is probably beneficial to survival. The utilisation of follow-up surveillance in breast cancer patients and its potential impact on survival deserve further investigation. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 10, 2009 Category: Cancer & Oncology Authors: Wenli Lu, Michael Schaapveld, Liesbeth Jansen, Emad Bagherzadegan, Marko Mirza Sahinovic, Peter C. Baas, Leo M.H.C. Hanssen, Hans C.J. van der Mijle, Jan D. Brandenburg, Theo Wiggers, Geertruida H. De Bock Tags: Clinical oncology Source Type: journals

Description of the national situation of cervical cancer screening in the member states of the European UnionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This report up-dates information on the national situation of cervical cancer screening in the member states of the European Union. There is yet high diversity in the status of cervical screening, and rapid changes expected to occur in the situation in many countries. It is important to underline differences in the health care and other components in order to allow a proper interpretation of the summary results published elsewhere in this Special Issue. The brief national descriptions along with up-dated information on the recent references are available from all but one member states. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 9, 2009 Category: Cancer & Oncology Authors: Ahti Anttila, Guglielmo Ronco, Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE) Source Type: journals

Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral gliomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Aim of the study: Tumour angiogenesis and invasion are key features of glioblastoma multiforme (GBM). Angiogenesis inhibitors increase progression-free survival (PFS) of recurrent GBM patients. VEGF inhibition controls the bulk tumour growth by inhibition of angiogenesis, but does not inhibit the invasive tumour component. We investigated if invasive tumour growth can be controlled by combining anti-VEGF treatment with irradiation of tumour plus surrounding brain in an orthotopic murine model for GBM.Methods and materials: GBM cell line U251-NG2 was inoculated through a guide screw in the right frontal lobe of 53...
Source: European Journal of Cancer - September 7, 2009 Category: Cancer & Oncology Authors: Joost J.C. Verhoeff, Lukas J.A. Stalpers, An Claes, Koos E. Hovinga, Gijsbert D. Musters, W. Peter Vandertop, Dick J. Richel, William P.J. Leenders, Wouter R. van Furth Tags: Experimental oncology Source Type: journals

Targeting the WNT/β-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic optionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Among aberrantly regulated signalling pathways in cancer the WNT/β-catenin pathway plays an outstanding role, since it was shown to be critically involved in a wide range of neoplasias. While the underlying mechanisms vary, overexpression of WNTs was found to mediate active signalling in some of these diseases. Other cancers show a mutation in pathway members further downstream, such as APC, Axin or β-catenin, leading to aberrant signalling activation. Another mechanism initiating activation of WNT/β-catenin signalling is the silencing of expression of negative WNT/β-catenin regulators, such as DKK and WIF1, ...
Source: European Journal of Cancer - September 2, 2009 Category: Cancer & Oncology Authors: Iris Gehrke, Rajesh Kumar Gandhirajan, Karl-Anton Kreuzer Tags: Reviews Source Type: journals

CalendarEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - August 31, 2009 Category: Cancer & Oncology Source Type: journals

Ejc news, issue 14, 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - August 31, 2009 Category: Cancer & Oncology Source Type: journals

Editorial boardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - August 31, 2009 Category: Cancer & Oncology Source Type: journals

Process performance of cervical screening programmes in EuropeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Standardised tables of aggregated data were collected from 15 European national or regional cervical screening programmes and key performance indicators computed as reported in European Union (EU) Guidelines, 2nd edition.Cytological results varied widely between countries both for the total proportion of abnormal tests (from 1.2% in Germany (Mecklenburg-Vorpommern) to 11.7% in Ireland-Midwest Region) and for their distribution by grade. Referral rates for repeat cytology (ranging from 2.9% of screened women in the Netherlands to 16.6% in Slovenia) or for colposcopy (ranging from 0.8% in Finland to 4.4% in Romania...
Source: European Journal of Cancer - August 26, 2009 Category: Cancer & Oncology Authors: Guglielmo Ronco, Marjolein van Ballegooijen, Nikolaus Becker, Arkadiusz Chil, Muriel Fender, Pamela Giubilato, Juozas Kurtinaitis, Lesz Lancucki, Elsebeth Lynge, Antonio Morais, Marian O’Reilly, Pär Sparen, Ofelia Suteu, Matejka Rebolj, Piret Veerus, M Source Type: journals

HPV infection in EuropeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: In order to estimate the impact of primary cervical cancer screening with human papillomavirus (HPV) testing, and implementation of the current HPV vaccines, we have summarised the most recent and largest HPV studies in Europe. Eighteen studies including between 897 and 46,900 women from 14, mostly Northern and Western European, countries were included. Everywhere, high-risk (HR) HPV prevalence peaked before age 25 or 30years with steady declines thereafter. For women in the 30–64-year age-range, for whom primary HPV testing is considered, age-adjusted HR HPV prevalence ranged from 2% in Spain to approximately ...
Source: European Journal of Cancer - August 25, 2009 Category: Cancer & Oncology Authors: Hugo De Vuyst, Gary Clifford, Ni Li, Silvia Franceschi Source Type: journals

CalendarEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - August 22, 2009 Category: Cancer & Oncology Source Type: journals

Ejc news issue 13, 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - August 22, 2009 Category: Cancer & Oncology Source Type: journals

Editorial boardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: European Journal of Cancer)
Source: European Journal of Cancer - August 22, 2009 Category: Cancer & Oncology Source Type: journals

Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, a large homogenous group of 103 laryngeal carcinomas has been investigated in the presence of hypoxia by pimonidazole binding and the usefulness of Carbonic anhydrase IX (CA-IX) and vascular parameters as surrogate markers of hypoxia. These parameters are further related to clinical and biological characteristics.One hundred and three patients with T2–T4 larynx carcinoma were included. They were given the hypoxia marker pimonidazole intravenously (i.v.) 2h prior to taking a biopsy. Expression of all the parameters was examined by immunohistochemistry, excluding large necrotic areas. Among tumours a large v...
Source: European Journal of Cancer - August 20, 2009 Category: Cancer & Oncology Authors: Ilse J. Hoogsteen, Jasper Lok, Henri A.M. Marres, Robert P. Takes, Paul F.J.W. Rijken, Albert J. van der Kogel, Johannes H.A.M. Kaanders Tags: Experimental oncology Source Type: journals

Challenges in starting organised screening programmes for cervical cancer in the new member states of the European UnionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Following the 2003 Recommendation of the Council of the European Union on cancer screening, equal access to organised cervical cancer screening is supposed to be ensured for all women at risk in all member states. However, the first IARC report on the implementation of the Council Recommendation suggests that a remarkable proportion of women in the new member states are not yet covered with the free Pap tests offered either in organised or opportunistic manners. Cervical cancer incidence and mortality rates in most of these countries are among the highest in Europe. The purpose of this paper is to identify some c...
Source: European Journal of Cancer - August 20, 2009 Category: Cancer & Oncology Authors: Florian Al. Nicula, Ahti Anttila, Luciana Neamtiu, Maja Primic Žakelj, Ruth Tachezy, Arkadiusz Chil, Magdalena Grce, Vesna Kesić Source Type: journals

Cervical cancer screening policies and coverage in EuropeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The aim of the study was to compare current policy, organisation and coverage of cervical cancer screening programmes in the European Union (EU) member states with European and other international recommendations. According to the questionnaire-based survey, there are large variations in cervical cancer screening policies and inadequacies in the key organisational elements of the programme such as registration and monitoring required for quality-assurance and fail-safe mechanisms. Based on data from available screening registers, coverage of the screening test taken within the population-based programme was below...
Source: European Journal of Cancer - August 20, 2009 Category: Cancer & Oncology Authors: Ahti Anttila, Lawrence von Karsa, Auni Aasmaa, Muriel Fender, Julietta Patnick, Matejka Rebolj, Florian Nicula, Laszlo Vass, Zdravka Valerianova, Lydia Voti, Catherine Sauvaget, Guglielmo Ronco Source Type: journals

Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The likelihood of identifying peptides of sufficient quality for the development of effective cancer vaccines by screening of phage display libraries is low. Here, we introduce the sequential application of systematic amino acid substitution by SPOT synthesis. After the substitution of two amino acids within the sequence of a phage display-derived mimotope of disialoganglioside GD2 (mimotope MA), the novel mimotope C3 showed improved GD2 mimicry in vitro. Peptide vaccination with the C3 mimotope induced an 18-fold increased anti-GD2 serum response associated with reduction of primary tumour growth and spontaneous...
Source: European Journal of Cancer - August 19, 2009 Category: Cancer & Oncology Authors: Matthias Bleeke, Stefan Fest, Nicole Huebener, Christiane Landgraf, Burkhart Schraven, Gerhard Gaedicke, Rudolf Volkmer, Holger N. Lode Tags: Experimental oncology Source Type: journals

Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1α involvement in CYP3A4 repressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, HepaRG cells cultured under hypoxia might mimic metabolic changes occurring within poorly irrigated differentiated HCCs. Furthermore, hypoxia down-regulates hepatic DMEs, a phenomenon that might compromise chemotherapy effectiveness in HCC treatment. Thus, HepaRG cells might represent a new in vitro model to test anticancer agents in hypoxic versus normoxic conditions. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 19, 2009 Category: Cancer & Oncology Authors: Claire Legendre, Tamaki Hori, Pascal Loyer, Caroline Aninat, Seiichi Ishida, Denise Glaise, Catherine Lucas-Clerc, Karim Boudjema, Christiane Guguen-Guillouzo, Anne Corlu, Fabrice Morel Tags: Experimental oncology Source Type: journals

APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: ApcMin mice are widely used for mechanism and efficacy studies associated with the development of chemopreventive agents. APC10.1 cells have been derived from ApcMin mouse adenomas and retain the heterozygous Apc genotype. We tested the hypothesis that this cell type may provide an in vitro model to predict chemopreventive activity of agents in the ApcMin mouse in vivo.The growth inhibitory properties of 14 putative colorectal cancer chemopreventive agents, tricin, apigenin, 3′,4′,5′,5,7-pentamethoxyflavone, resveratrol, curcumin, 3,4-methylenedioxy-3′,4′,5′-trimethoxychalcone (DMU135), 3,4,5,4′-tet...
Source: European Journal of Cancer - August 19, 2009 Category: Cancer & Oncology Authors: Stewart Sale, Isabel L. Fong, Carla de Giovanni, Lorena Landuzzi, Karen Brown, William P. Steward, Andreas J. Gescher Tags: Short communication Source Type: journals

What’s next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccinationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The future of cervical cancer control may become a diversified strategy, one for non-vaccinated birth cohorts and another for vaccinated cohorts. It will take another 50 years before the non-vaccinated cohorts have passed the screening age. With the current uncertainty concerning the long term protection from HPV-vaccination it will furthermore be precautionary to continue screening practice for the first cohorts of HPV-vaccinated women. Organised vaccination and screening programmes with good record keeping are necessary to optimise the future control of cervical cancer. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 19, 2009 Category: Cancer & Oncology Authors: Elsebeth Lynge, Ahti Antilla, Marc Arbyn, Nereo Segnan, Guglielmo Ronco Source Type: journals

The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 surveyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Three surveys have been undertaken in European Union (EU) member states since January 2007, within the European Commission funded Vaccine European New Integrated Collaboration Effort (VENICE) project, to monitor the decision status regarding the introduction of human papillomavirus (HPV) vaccination into national immunisation schedules. A web-based questionnaire was developed and completed online by the 28 countries participating in VENICE. According to the last update (31st December 2008), 15 countries have decided to introduce HPV vaccination into their national immunisation schedule, while another six have sta...
Source: European Journal of Cancer - August 19, 2009 Category: Cancer & Oncology Authors: D. Lévy-Bruhl, V. Bousquet, L.A. King, D. O’Flanagan, S. Bacci, P.L. Lopalco, S. Salmaso, the country specific VENICE gate keepers and contact points Source Type: journals

The challenges of organising cervical screening programmes in the 15 old member states of the European UnionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Cervical cancer incidence and mortality can be reduced substantially by organised cytological screening at 3 to 5 year intervals, as was demonstrated in the Nordic countries, the United Kingdom, the Netherlands and parts of Italy. Opportunistic screening, often proposed at yearly schedules, has also reduced the burden of cervical cancer in some, but not all, of the other old member states (belonging to the European Union since 1995) but at a cost that is several times greater. Well organised screening programmes have the potential to achieve greater participation of the target population at regular intervals, equ...
Source: European Journal of Cancer - August 19, 2009 Category: Cancer & Oncology Authors: Marc Arbyn, Matejka Rebolj, Inge M.C.M. De Kok, Murielle Fender, Nikolaus Becker, Marian O’Reilly, Bengt Andrae Source Type: journals

Trends of cervical cancer mortality in the member states of the European UnionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Remarkable contrasts were observed on cervical cancer mortality, in particular, between the old and new member states of the EU, which might probably be explained by differences in preventive strategies. This contrast might increase in the future, unless adequate preventive measures are adopted. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 19, 2009 Category: Cancer & Oncology Authors: Marc Arbyn, Amidu O. Raifu, Elisabete Weiderpass, Freddie Bray, Ahti Anttila Source Type: journals

Cervical cancer screening in Europe – Changes over the last 9 yearsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The first studies showing a large impact of high-quality cervical cancer screening activity were published in the 1960s and 1970s and documented a decrease in the incidence of invasive squamous-cell carcinoma of the cervix uteri among women screened of up to about 90%, in comparison with those unscreened or the rates before screening. It has been estimated that high quality screening can reduce cervical cancer incidence by 80% or possibly more in the whole screened population. This large reduction, the relatively early age of occurrence of cervical cancer and the fact that cervical cancer screening prevents invasive cancer...
Source: European Journal of Cancer - August 19, 2009 Category: Cancer & Oncology Authors: Guglielmo Ronco, Ahti Anttila Tags: Editorial Comment Source Type: journals

Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Aim: Adjuvant therapy is not routinely recommended in UICC stages I and II colon cancer, but may be considered for high-risk patients. Our aim is to identify clinicopathologic characteristics in colon cancer stages I and II, which are associated with an increased risk of tumour recurrence and tumour-related death.Methods: We analysed our prospectively documented clinical database of 775 patients with colon cancer stages I and II, which underwent curative resection between 1982 and 2006. No adjuvant chemotherapy was applied. The median follow-up time was 80months.Results: For the entire study group, 5- and 10-year...
Source: European Journal of Cancer - August 17, 2009 Category: Cancer & Oncology Authors: Ralf Gertler, Robert Rosenberg, Tibor Schuster, Helmut Friess Tags: Clinical oncology Source Type: journals

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve ...
Source: European Journal of Cancer - August 17, 2009 Category: Cancer & Oncology Authors: Xavier B. Pivot, Rubi K. Li, Eva S. Thomas, Hyun-Cheol Chung, Luis E. Fein, Valorie F. Chan, Jacek Jassem, Fernando Hurtado de Mendoza, Pralay Mukhopadyay, Henri H. Roché Tags: Reviews Source Type: journals